Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma
- 12 August 2005
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 8 (1), 90-99
- https://doi.org/10.1002/jgm.817
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Cancer Immunotherapy: A Treatment for the MassesScience, 2004
- Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphomaMolecular Therapy, 2003
- Cytokine requirements for the growth and development of mouse NK cells in vitroJournal of Leukocyte Biology, 2003
- A Critical Role for IL-21 in Regulating Immunoglobulin ProductionScience, 2002
- The Common γ Chain (γc) Is a Required Signaling Component of the IL-21 Receptor and Supports IL-21-Induced Cell Proliferation via JAK3Biochemistry, 2002
- Interleukin-12 in anti-tumor immunity and immunotherapyCytokine & Growth Factor Reviews, 2002
- IL-21 Limits NK Cell Responses and Promotes Antigen-Specific T Cell ActivationImmunity, 2002
- Cutting Edge: The Common γ-Chain Is an Indispensable Subunit of the IL-21 Receptor ComplexThe Journal of Immunology, 2001
- Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte functionNature, 2000
- Cytokine Therapy for CancerCurrent Pharmaceutical Design, 2000